Clinical Report: FDA Approves First Oral PCSK9 Inhibitor
Overview
The FDA has approved enlicitide (LIPFENDRA) as the first oral PCSK9 inhibitor for reducing LDL cholesterol in adults with hypercholesterolemia. This approval is based on reductions in LDL-C observed in phase 3 trials.
Background
Hypercholesterolemia is a major risk factor for cardiovascular disease, necessitating effective treatments to lower LDL cholesterol levels. PCSK9 inhibitors have emerged as a class of lipid-lowering agents, with the approval of enlicitide marking a new option for patients requiring additional LDL-C reduction.
Data Highlights
Trial
Placebo-Adjusted LDL-C Reduction
Adverse Reactions
CORALreef Lipids
56% at week 24
Similar rates between groups
CORALreef HeFH
59% at week 24
Diarrhea in 7% vs 2%, Dizziness in 9% vs 4%
Key Findings
Enlicitide is the first FDA-approved oral PCSK9 inhibitor.
It is indicated as an adjunct to diet and exercise for adults with hypercholesterolemia.
In CORALreef Lipids, enlicitide showed a 56% placebo-adjusted reduction in LDL-C at week 24.
In CORALreef HeFH, a 59% placebo-adjusted reduction in LDL-C was observed.
Adverse reaction rates were similar between enlicitide and placebo groups.
An ongoing trial is assessing the impact of enlicitide on cardiovascular morbidity and mortality.
Clinical Implications
Monitoring for gastrointestinal side effects, such as diarrhea and dizziness, may be necessary.
Conclusion
Enlicitide is an oral PCSK9 inhibitor approved for adults with hypercholesterolemia, pending further data on its long-term cardiovascular outcomes.
